Literature DB >> 16163170

Update on monoclonal antibody therapy in chronic lymphocytic leukemia.

Clive S Zent1, Neil E Kay.   

Abstract

Monoclonal antibodies are an evolving treatment modality in chronic lymphocytic leukemia that has the potential to provide more effective and safer targeted therapy. This review provides historical context and detailed analysis of current developments, as well as an outline for future prospects and expectations in this exciting new arena of therapeutics.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16163170

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


  2 in total

1.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

2.  Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.

Authors:  Heather L Pulaski; Gregory Spahlinger; Ines A Silva; Karen McLean; Angela S Kueck; R Kevin Reynolds; George Coukos; Jose R Conejo-Garcia; Ronald J Buckanovich
Journal:  J Transl Med       Date:  2009-06-19       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.